Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - chlorphenamine maleate, quantity: 2 mg; pseudoephedrine hydrochloride, quantity: 30 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: povidone; erythrosine aluminium lake; microcrystalline cellulose; purified water; crospovidone; magnesium stearate; pregelatinised maize starch; stearic acid - temporary relief from the following cold & flu symptoms: nasal congestion, sinus pain, runny nose, headache, body aches & pains. reduces fever. the night tablets also provide relief from sneezing and itchy or watery eyes, and assist rest by providing relief from these symptoms.

Kenya - Kiingereza - Pharmacy and Poisons Board

dawa limited p.o. box 16633-00620 nairobi, kenya - erythromycin stearate - tablet - erythromycin (as stearate) bp 250mg per tablet - antibacterials for systemic use: macrolides

Marekani - Kiingereza - NLM (National Library of Medicine)

corepharma, llc - felbamate (unii: x72rbb02n8) (felbamate - unii:x72rbb02n8) - felbamate 400 mg

Marekani - Kiingereza - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - felbamate (unii: x72rbb02n8) (felbamate - unii:x72rbb02n8) - felbamate 400 mg

Marekani - Kiingereza - NLM (National Library of Medicine)

viona pharmaceuticals inc - felbamate (unii: x72rbb02n8) (felbamate - unii:x72rbb02n8) - felbamate tablets, usp are not indicated as a first line antiepileptic treatment (see warnings ). felbamate tablets, usp are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. if these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with lennox-gastaut syndrome in children. felbamate is contraindicated in patients with known hypersensitivity to felbamate, its ingredients, or known sensitivity to other carbamates. it should not be used in patients with a history of any blood dyscrasia or hepat

Marekani - Kiingereza - NLM (National Library of Medicine)

vistapharm, inc. - felbamate (unii: x72rbb02n8) (felbamate - unii:x72rbb02n8) - felbamate oral suspension is not indicated as a first line antiepileptic treatment (see warnings ). felbamate oral suspension is recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. if these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgement, felbamate oral suspension can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with lennox-gastaut syndrome in children. felbamate oral suspension is contraindicated in patients with known hypersensitivity to felbamate, its ingredients, or known sensitivity to other carbamates. it should not be used in patients with a h

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; kaolin; maize starch - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: hypromellose; stearic acid; indigo carmine aluminium lake; purified talc; calcium silicate; citric acid monohydrate; amaranth aluminium lake; macrogol 6000; povidone; hyprolose; titanium dioxide; diethyl phthalate; polyvinyl acetate phthalate; magnesium stearate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 500 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; silicon dioxide; maltodextrin - indications as at 01 jan 1991 : frusemide in a high-dosage formulation such as urex forte ( 500 mg tablets ) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l / day dialysis has to be used.